Oncology Publications, Abstracts, and Posters
Monogram Biosciences has presented data to demonstrate our portfolio of VeraTag assays at recent clinical and scientific meetings. The publications and abstracts support the clinical utility and flexibility of VeraTag™ technology, our proprietary, novel, proximity-based assay which quantifies functional protein-protein interactions and protein expression.The publications listed below are available to download, or a PDF may be requested by email.
2009
| Multiple Subtypes of HER-2/neu-positive Metastatic Breast Cancer |
| A. Lipton, M. Bates et al. 32nd Annual San Antonio Breast Cancer Symposium Poster 2030 |
| Download PDF |
| Discordant HER2 total and HER2 homodimer levels by HERmark analysis in matched primary and metastatic breast cancer |
| K. Leitzel, A. Lipton et al. 32nd Annual San Antonio Breast Cancer Symposium Poster 2131 |
| Download PDF |
| Breast cancer patients with very high tumor HER2 expression levels might not benefit from treatment with trastuzumab plus chemotherapy: A retrospective exploratory analysis of the FinHer trial |
| H. Joensuu, M. Bates, et al. 32nd Annual San Antonio Breast Cancer Symposium Poster 5083 |
| Download PDF |
| Relationship between quantitative HER2 protein expression and clinical outcome following trastuzumab treatment in ER-positive and ER-negative sub-groups of patients with metastatic breast cancer |
| M. Bates, A. Lipton et al. 32nd Annual San Antonio Breast Cancer Symposium Poster 5136 |
| Download PDF |
| Quantitation of p95HER2, a truncated form of HER2, in FFPE specimens using a p95-specific antibody and correlations with outcome in a cohort of tratuzumab-treated metastatic breast cancer patients |
| Sperinde J, Jin X, Banerjee J, et al. 2009 ASCO Breast Cancer Symposium, October 8-10, 2009, Poster #56 |
| Download PDF |
| Quantitative measurement of HER3 total protein (H3T) and association with clinical outcome in HER2 positive metastatic breast cancer patients treated with trastuzumab |
| Goodman L, Weston J, Sperinde J, et al. 2009 ASCO Annual Meeting, May 29-June 2, 2009, Abstract #1021 |
J Clin Oncol 27:15s, 2009 (suppl; abstr 1021) |
| Download PDF |
| Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab |
| Sperinde J, Ali S, Leitzel K, et al. 2009 ASCO Annual Meeting, May 29-June 2, 2009, Abstract #1059 |
J Clin Oncol 27:15s, 2009 (suppl; abstr 1059) |
| Download PDF |
| Correlation of quantitative total HER2 expression and HER2 homodimers with histopathologic characteristics of breast cancers in the FinHer study |
| Huang W, Weidler J, Lie Y, et. al. 2009 ASCO Annual Meeting, May 29-June 2, 2009, Abstract #11061 |
J Clin Oncol 27:15s, 2009 (suppl; abstr 11061) |
| Download PDF |
| Quantitative, sensitive and reproducible measurement of epidermal growth factor/HER1 and total expression in formalin-fixed, paraffin-embedded tumors using a novel proximity-based assay |
| Shi Y, Wallwebber J, Bose J, et al. 100th Annual American Association Cancer Research Meeting, April 18-22, 2009, Symposium Poster #5244 |
| Download PDF |
| Quantitative measurement of phosphorylated HER1, HER2 and HER1-HER2 heterodimers in formalin-fixed, paraffin-embedded (FFPE) breast and head/neck tumors using proximity-based immunoassays |
| Eli L, Trang D, Strommen K, et. al. 100th Annual American Association Cancer Research Meeting, April 18-22, 2009, Symposium Poster #5247 |
| Download PDF |
| Profiling PI3K pathway activation in formalin-fixed, paraffin-embedded tumor cell lines and breast tumors using novel proximity assays |
| Williams S, Mukherjee A, Youssouf Badal, M, et. al. 100th Annual American Association Cancer Research Meeting, April 18-22, 2009, Symposium Poster #5251 |
| Download PDF |
| A Novel Proximity Assay for the Detection of Proteins and Protein Complexes: Quantitation of HER1 and HER2 Total Protein Expression and Homodimerization in Formalin-fixed, Paraffin-Embedded Cell Lines and Breast Cancer Tissue |
| Shi Y, Huang W, Tan Y, et al. Diagn Mol Pathol, Volume 18, Number 1, March 2009 |
| Click here to request a copy |
| Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH |
| Desmedt C, Sperinde J, Piette F, et al. Diagn Mol Pathol, Volume 18, Number 1, March 2009 |
| Click here to request a copy |
2008
| HER2 protein expression and homodimer levels predict response to trastuzumab in centrally tested FISH-positive metastatic breast cancer patients. |
| Lipton A, Ali S, Leitzel K, et al. 31st Annual San Antonio Breast Cancer Symposium Abstract #32, ORAL PRESENTATION |
| Download PDF |
| Quantitative HER2 homodimer levels correlate with time to first recurrence in HER2-positive breast cancer patients who did not receive trastuzumab in the adjuvant setting. |
| Bates M, Sperinde J, Leitzel K, et al. 31st Annual San Antonio Breast Cancer Symposium Poster #1074 |
| Download PDF |
| Quantitative measurements of HER2 expression and HER2 homodimer using a novel proximity based assay: comparison with HER2 status by immunohistochemistry and chromogenic in situ hybridization in the FinHer study. |
| Joensuu H, Weidler J, Lie Y, et al. 31st Annual San Antonio Breast Cancer Symposium Poster #2071 |
| Download PDF |
| Proximity-based assays for the detection of activated HER3, HER2/3 heterodimers and HER3/PI3K complexes in FFPE cell line controls and tumors |
| Mukherjee A, Nguyen X, Williams S, et al. 31st Annual San Antonio Breast Cancer Symposium Poster #4040 |
| Download PDF |
|
|||
| Ghosh R, Narasanna A, Shizen E, et al. American Association for Cancer Research "Targeting the PI3-Kinase Pathway in Cancer" November 10 -14, 2008 Poster | |||
| Download PDF |
| Development of novel-proximity based immunoassays for activated HER1, HER2, and HER1-HER2 heterodimers in formalin-fixed, paraffin embedded (FFPE) cells |
| Eli L, Frankson K, Dao-Pick T, et al. 20th EORTC-NCI-AACR symposium on "Molecular targets and Cancer Therapeutics" Geneva, Switzerland, 21-24 October 2008 Poster #88 |
| Download PDF |
| Development of highly quantitative, sensitive, and reproducible assays for the detection of EGFR/HER1 and ErbB3/HER3 in formalin-fixed, paraffin-embedded (FFPE) tumor tissue |
| Shi Y, Mukherjee A, Weston J, et al. 20th EORTC-NCI-AACR symposium on "Molecular targets and Cancer Therapeutics" Geneva, Switzerland, 21-24 October 2008 Poster #103 |
| Download PDF |
| Comparison of Central HER-2 Tests with Quantitative HER-2 Expression and HER-2 Homodimer Measurements Using a Novel Proximity Based Assay |
| Huang W, Reinholz M, Weidler J, et al. Poster #40, College of American Pathology Meeting 2008 |
| Download PDF |
| Total HER2 and HER2 homodimer levels predict response to trastuzumab |
| Leitzel K, Lipton A, Koestler W, et al. American Society of Clinical Oncology 44th Annual Meeting, Chicago, IL June 2, 2008 Oral Presentation |
|
Download Slide Deck Download PDF |
2007
| The ASCO/CAP Guidelines for HER2 Testing in Breast Cancer |
| Wolff A, Hammond M, Schwartz J, et al. Journal of Clinical Oncology Vol. 25, Number 1, January 2007 |
| Download PDF |
| HER2 expression and HER2-HER2 dimerization identifies subpopulations of metastatic breast cancer patients with different probabilities of long-term survival following trastuzumab treatment and with different requirements for concomitant chemotherapy. |
| Bates M, Desmedt C, Sperinde J et al. 2007 ASCO Annual Meeting Proceedings Poster #10577 |
| Download PDF |
|
Increased detection of breast cancer markers human epidermal growth factor receptor dimer and downstream signaling proteins utilizing the VeraTag technology with dextran modified antibodies.
Wallweber J, Dang T, Gupta S, et al. 30th San Antonio Breast Cancer Symposium taking place in San Antonio, TX, December 12- 16, 2007. Abstract # 5002 |
| Download PDF |
|
Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2:HER2 dimerization in a clinic-based cohort of patients with metastatic breast cancer.
Toi M, Sperinde J, Huang W, et al. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Vol. 25, (18S), 2007: 1025 |
| Download PDF |
|
Patterns of HER-family receptor dimerization in trastuzumab susceptible and trastuzumab resistant cell lines.
Dua R, Nhonthachit P, Rinehart C, et al. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Vol.25, (18S), 2007 |
| Download PDF |
